Current Edition

Upcoming Events



GSK wagers $2.1B on Affinivax and its next-generation pneumonia vaccine

GSK has agreed to acquire Affinivax in a deal announced Tuesday, betting more than $3 billion that the eight-year-old startup’s technology can lead to a …

Continue Reading →

Pfizer to exit GSK consumer health joint venture after spinoff

Dive Brief: Pfizer plans to sell its shares in a consumer health joint venture with GlaxoSmithKline after the business is spun off into a new …

Continue Reading →

Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs

Pfizer has agreed to acquire Biohaven Pharmaceuticals for $11.6 billion in a deal that turns an existing alliance on a fast-selling migraine drug into a …

Continue Reading →

UK bid to battle antibiotic resistance yields first subscription-style plan

The U.K. took a small step forward in its efforts to spur development of new antibiotics, announcing on Tuesday a plan to pay Pfizer and …

Continue Reading →

Pfizer buys a private biotech and its RSV drug research

Dive Brief: Pfizer said Thursday it will spend as much as $525 million to buy the privately held biotech ReViral, adding experimental treatments for respiratory …

Continue Reading →

Pfizer claims study success for drug key to Arena buyout

Dive Brief: Pfizer said Wednesday an experimental drug central to its $7 billion purchase of Arena Pharmaceuticals succeeded in a crucial Phase 3 trial in …

Continue Reading →

Alnylam sues Pfizer, Moderna over technology used in COVID vaccines

Dive Brief: Alnylam is accusing Pfizer and Moderna of violating a patent it holds for technology that Alnylam claims the two companies use in their …

Continue Reading →

Moderna, citing need for ‘flexibility,’ seeks broad clearance of fourth COVID shot

Dive Brief: Moderna has asked the Food and Drug Administration to clear a fourth dose of its COVID-19 vaccine for adults 18 and over, a …

Continue Reading →

After slower-than-expected review, Pfizer and Arena close buyout deal

Dive Brief: Arena Pharmaceuticals’ $7 billion sale to Pfizer closed on Friday, ending a slightly protracted regulatory review that raised questions about whether the deal would …

Continue Reading →

Pfizer forecasts $100B in sales, fueled by COVID-19 vaccine, pill

Dive Brief: Pfizer on Tuesday forecast that its revenue this year will grow to total between $98 billion and $102 billion, which, measured at the …

Continue Reading →

Pfizer lures research chief from Roche, prompting high-level reshuffle

Dive Brief: Pfizer is hiring William Pao, currently Roche’s head of pharmaceutical research and early development, to serve as its chief development officer and executive …

Continue Reading →

With new trial, Pfizer and BioNTech will test whether an omicron vaccine is needed

Dive Brief: Pfizer and BioNTech have begun enrolling patients in a study testing a new version of their COVID-19 vaccine specifically tailored to the omicron …

Continue Reading →

Moderna follows Pfizer in beginning trial of omicron vaccine

Dive Brief: Moderna on Wednesday said it has begun a trial testing a new version of its COVID-19 vaccine that’s tailored to the omicron variant, …

Continue Reading →

FDA approves AbbVie, Pfizer drugs for eczema, creating competition for Sanofi

Dive Brief: The top-selling product for French pharmaceutical giant Sanofi now has two more competitors in the U.S. market, as the Food and Drug Administration …

Continue Reading →

Pfizer’s big bet on mRNA, Biogen ‘proven wrong’ on Aduhelm price and the next cell therapies

Biotechnology stocks ended the first day of the J.P. Morgan Healthcare Conference in the green, but only barely. By Monday afternoon, a closely followed index of …

Continue Reading →
COVID-19 pills

COVID-19 pills from Pfizer, Merck authorized by FDA in major pandemic milestone

Paxlovid and molnupiravir are the first oral treatments for COVID-19, potentially valuable new tools as the fast-spreading omicron variant fuels a sharp surge in cases …

Continue Reading →
COVID-19 pill

In final analysis, Pfizer’s COVID-19 pill remains highly effective

Final study results show Pfizer’s experimental COVID-19 pill remained as effective as indicated by preliminary data last month, a major relief after promising data for …

Continue Reading →

Lilly deepens research ties in China with biotech deal

Lilly’s deal with Regor is another example of large pharmaceutical companies in the U.S. and Europe showing interest in Chinese biotechs for their research, rather …

Continue Reading →

Arena, completing its turnaround, sells to Pfizer for nearly $7 billion

Pfizer has agreed to acquire Arena Pharmaceuticals for about $6.7 billion in a deal that validates the San Diego biotech’s plan to reshape itself around …

Continue Reading →

AbbVie’s blockbuster weighed down by safety concerns for a similar Pfizer drug

For years, AbbVie’s business has relied on Humira. One of the world’s top-selling medicines, Humira brought in close to $20 billion for AbbVie in each …

Continue Reading →